PriceTargets.com logo

Compass Therapeutics - CMPX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $11.38
  • Forecasted Upside: 360.53%
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$2.47 As of 03/13/2025 05:00 PM ET
▼ -0.04 (-1.59%)

This chart shows the closing price for CMPX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
JanFebMar$2.47Closing price on 03/13/25:
Get New Compass Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CMPX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CMPX

Analyst Price Target is $11.38
▲ +360.53% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Compass Therapeutics in the last 3 months. The average price target is $11.38, with a high forecast of $32.00 and a low forecast of $4.00. The average price target represents a 360.53% upside from the last price of $2.47.

This chart shows the closing price for CMPX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
3/246/249/2412/243/253/26$0.56$8.42$16$24$32Closing price on 03/13/25: $2.47High$32.00Average$11.38Low$4.00




Current Consensus is Moderate Buy

The current consensus among 9 contributing investment analysts is to moderate buy stock in Compass Therapeutics. This rating has held steady since November 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/19/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/18/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/16/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/14/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/13/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/11/2025
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/13/2025

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/25/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
2/24/2025GuggenheimInitiated CoverageBuy$12.00
2/19/2025Piper SandlerInitiated CoverageOverweight$12.00
2/10/2025Jefferies Financial GroupBoost TargetBuy ➝ Buy$7.00 ➝ $8.00
1/8/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
1/8/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00
12/23/2024D. Boral CapitalInitiated CoverageBuy$32.00
11/15/2024Leerink PartnrsDowngradeStrong-Buy ➝ Hold
11/15/2024Leerink PartnersDowngradeOutperform ➝ Market Perform$5.00 ➝ $4.00
11/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
9/16/2024LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$5.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
8/7/2024WedbushReiterated RatingOutperform ➝ Outperform$8.00 ➝ $8.00
8/6/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
6/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00
4/16/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00
3/22/2024WedbushReiterated RatingOutperform ➝ Outperform$8.00
3/21/2024HC WainwrightReiterated RatingBuy ➝ Buy$10.00
8/3/2023HC WainwrightReiterated RatingBuy$10.00
3/16/2023HC WainwrightReiterated RatingBuy$10.00
1/31/2023Jefferies Financial GroupInitiated CoverageBuy$8.00
1/26/2023Stifel NicolausInitiated CoverageBuy$9.00
12/16/2022EF Hutton Acquisition Co. IInitiated CoverageBuy$10.30
11/16/2022LADENBURG THALM/SH SHBoost Target$9.00
11/10/2022Raymond JamesBoost TargetOutperform$5.00 ➝ $8.00
11/3/2022HC WainwrightLower TargetBuy$12.00 ➝ $10.00
6/22/2022B. RileyReiterated RatingBuy
5/23/2022HC WainwrightReiterated RatingBuy$12.00
3/15/2022LADENBURG THALM/SH SHInitiated CoverageBuy$7.00
1/21/2022HC WainwrightInitiated CoverageBuy$11.00
1/18/2022B. RileyInitiated CoverageBuy$10.00
12/22/2021Raymond JamesInitiated CoverageOutperform$5.00
12/20/2021Leerink PartnersInitiated CoverageOutperform$12.00
12/15/2021WedbushInitiated CoverageOutperform$8.00
11/19/2021Roth CapitalInitiated CoverageBuy$15.00
11/16/2021HC WainwrightInitiated CoverageBuy$11.00
10/20/2021HC WainwrightInitiated CoverageBuy$11.00
10/1/2021BenchmarkInitiated CoverageBuy$11.00
(Data available from 3/14/2020 forward)

News Sentiment Rating

0.36 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/15/2024
  • 2 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/14/2024
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/14/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/13/2024
  • 4 very positive mentions
  • 12 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/13/2024
  • 2 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/12/2025
  • 4 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/11/2025
  • 3 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/13/2025

Current Sentiment

  • 3 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Compass Therapeutics logo
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $2.47
Low: $2.46
High: $2.56

50 Day Range

MA: $2.79
Low: $1.43
High: $3.90

52 Week Range

Now: $2.47
Low: $0.77
High: $4.08

Volume

458,930 shs

Average Volume

654,057 shs

Market Capitalization

$341.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.19

Frequently Asked Questions

What sell-side analysts currently cover shares of Compass Therapeutics?

The following equities research analysts have issued reports on Compass Therapeutics in the last year: D. Boral Capital, Guggenheim, HC Wainwright, Jefferies Financial Group Inc., LADENBURG THALM/SH SH, Leerink Partners, Leerink Partnrs, Piper Sandler, and Wedbush.
View the latest analyst ratings for CMPX.

What is the current price target for Compass Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Compass Therapeutics in the last year. Their average twelve-month price target is $11.38, suggesting a possible upside of 360.5%. D. Boral Capital has the highest price target set, predicting CMPX will reach $32.00 in the next twelve months. Leerink Partners has the lowest price target set, forecasting a price of $4.00 for Compass Therapeutics in the next year.
View the latest price targets for CMPX.

What is the current consensus analyst rating for Compass Therapeutics?

Compass Therapeutics currently has 2 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for CMPX.

What other companies compete with Compass Therapeutics?

Other companies that are similar to Compass Therapeutics include Dyne Therapeutics, Ardelyx, Evotec, ANI Pharmaceuticals and Iovance Biotherapeutics. Learn More about companies similar to Compass Therapeutics.

How do I contact Compass Therapeutics' investor relations team?

The company's listed phone number is 617-500-8099 and its investor relations email address is ir@compasstherapeutics.com. The official website for Compass Therapeutics is www.compasstherapeutics.com. Learn More about contacing Compass Therapeutics investor relations.